Cargando…
A novel caspase 8 selective small molecule potentiates TRAIL-induced cell death
Recombinant soluble TRAIL and agonistic antibodies against TRAIL receptors (DR4 and DR5) are currently being created for clinical cancer therapy, due to their selective killing of cancer cells and high safety characteristics. However, resistance to TRAIL and other targeted therapies is an important...
Autores principales: | Bucur, Octavian, Gaidos, Gabriel, Yatawara, Achani, Pennarun, Bodvael, Rupasinghe, Chamila, Roux, Jérémie, Andrei, Stefan, Guo, Bingqian, Panaitiu, Alexandra, Pellegrini, Maria, Mierke, Dale F., Khosravi-Far, Roya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4426715/ https://www.ncbi.nlm.nih.gov/pubmed/25962125 http://dx.doi.org/10.1038/srep09893 |
Ejemplares similares
-
Identification and Characterization of the Interaction Site between cFLIP(L) and Calmodulin
por: Gaidos, Gabriel, et al.
Publicado: (2015) -
killerFLIP: a novel lytic peptide specifically inducing cancer cell death
por: Pennarun, B, et al.
Publicado: (2013) -
A Cell Permeable Peptide Targeting the Intracellular Loop 2 of Endothelin B Receptor Reduces Pulmonary Hypertension in a Hypoxic Rat Model
por: Green, Daniel S., et al.
Publicado: (2013) -
Combination of Bortezomib and Mitotic Inhibitors Down-Modulate Bcr-Abl and Efficiently Eliminates Tyrosine-Kinase Inhibitor Sensitive and Resistant Bcr-Abl-Positive Leukemic Cells
por: Bucur, Octavian, et al.
Publicado: (2013) -
Modulation of TRAIL resistance in colon carcinoma cells: Different contributions of DR4 and DR5
por: van Geelen, Caroline MM, et al.
Publicado: (2011)